MedPath

European (EU) Post Approval Study of the INCRAFT® AAA Stent Graft System in Subjects With Abdominal Aortic Aneurysms

Completed
Conditions
Abdominal Aortic Aneurysms
Registration Number
NCT02477111
Lead Sponsor
Cordis Corporation
Brief Summary

INSIGHT is a postmarket clinical follow-up study in the European Union. The purpose of the study is to continue to evaluate the safety and effectiveness/performance of INCRAFT in subjects with abdominal aortic aneurysms requiring endovascular repair in routine clinical practice. Approximately 150 subjects will be enrolled and followed through 5-years post procedure. Up to 25 sites in Europe may participate.

Detailed Description

INSIGHT is a postmarket clinical follow-up study in the European Union. The purpose of the study is to continue to evaluate the safety and effectiveness/performance of INCRAFT in subjects with abdominal aortic aneurysms requiring endovascular repair in routine clinical practice. Approximately 150 subjects will be enrolled and followed through 5-years postprocedure. Up to 25 sites in Europe may participate. Subjects will be enrolled and followed at 1 month and 6 month post-procedure and annually up to 5 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
150
Inclusion Criteria
  1. Male or Female age 18 years or older
  2. Femoral access vessels should be adequate to fit the selected delivery system
  3. Proximal neck length ≥ 10mm
  4. Aortic neck diameters ≥ 17mm and ≤ 31mm
  5. Aortic neck suitable for suprarenal fixation
  6. Infrarenal and suprarenal neck angulation ≤ 60°
  7. Iliac fixation length ≥ 15mm
  8. Iliac diameters ≥ 7mm and ≤ 22mm
  9. Minimum overall AAA treatment length (proximal landing location to distal landing location) ≥ 128mm
  10. Morphology suitable for aneurysm repair
  11. Provide written informed consent and as applicable written confidentiality authorization prior to initiation of study procedures
  12. Subject is willing to comply with the specified follow-up evaluation schedule
Exclusion Criteria
  1. Subject has one of the following:

    1. Aneurysm sac rupture or leaking abdominal aortic aneurysm
    2. Mycotic, dissecting, or inflammatory abdominal aortic aneurysm
  2. Known allergy or intolerance to nickel titanium (nitinol), Polyethylene terephthalate (PET), or polytetrafluoroethylene (PTFE)

  3. Known contraindication to undergoing angiography or anticoagulation

  4. Existing AAA surgical graft and/or a AAA stent-graft system

  5. Women of child bearing potential whom are pregnant, lactating, or planning to become pregnant during the course of the trial

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of Participants With Major Adverse Events (MAE) Through 30 DaysWithin 30-days post-procedure

MAE rate through 30 days includes Death, Stroke/CVA, Myocardial Infarction, New onset renal failure (requiring dialysis)

Secondary Outcome Measures
NameTimeMethod
Number of Participants With Major Adverse Events Through 5 Years Post-ProcedureThrough 5 years post-procedure

MAE rate through 5 year includes Death, Stroke/CVA, Myocardial Infarction, New onset renal failure (requiring dialysis)

Absence of Aneurysm Sac RuptureWithin 1-year post-procedure
Amount of Time Fluoroscopy is Used During the ProcedureDuration of INCRAFT procedure is from bifurcate insertion to completion of angiography
Amount of Contrast Volume Used During the ProcedureDuration of INCRAFT procedure is from bifurcate insertion to completion of angiography
Number of Participants With Technical Success at Conclusion of Index ProcedureAt the conclusion of the index procedure

successful insertion of the delivery system through the vasculature and successful deployment of the device at the intended location

Absence of Type I or III EndoleakWithin 1 year post-procedure

defined as absence of type I or III endoleaks and absence of aneurysm enlargement (growth \>5mm compared to the 1-month size measurement) within 1-year post-procedure as assessed by the core lab

InCraft® - AAA Stent Graft SystemAssessed at 1 year

Single Arm EVAR Subjects who underwent procedure for the implant of InCraft® - AAA Stent Graft System

Number of Participants With Absence of Stent Graft Fracture Within 30-days and 1-year Post-procedureAssessed within 30-days and 1-year post-procedure
Duration of INCRAFT® Procedure (Minutes)Duration of INCRAFT procedure is from bifurcate insertion to completion of angiography

Duration of INCRAFT procedure is from bifurcate insertion to completion of angiography

Trial Locations

Locations (23)

Hospital Universitaire de Bordeaux

🇫🇷

Bordeaux, France

Universitätsklinikum Münster

🇩🇪

Münster, Germany

St.-Franziskus-Hospital

🇩🇪

Münster, Germany

University Hospital Schleswig - Holstein

🇩🇪

Kiel, Germany

University Medical Center Leipzig

🇩🇪

Leipzig, Germany

Universitätsklinikum Würzburg

🇩🇪

Würzburg, Germany

Kings College Hospital

🇬🇧

London, United Kingdom

Augusta Krankenhaus

🇩🇪

Düsseldorf, Germany

Hopital Prive Paul d'Egine

🇫🇷

Champigny-sur-Marne, France

Hull Royal Infirmary

🇬🇧

Hull, United Kingdom

Complejo Universitario Hospitalario de Ourense

🇪🇸

Ourense, Spain

Imperial College Healthcare NHS Trust St Mary's Hospital

🇬🇧

London, United Kingdom

Hospital Clinic University of Barcelona

🇪🇸

Barcelona, Spain

Azienda Ospedaliera Universitaria Careggi

🇮🇹

Firenze, Italy

Istituto Scientifico H San Raffaele

🇮🇹

Milano, Italy

Ospedale S. Maria della Misericordia

🇮🇹

Perugia, Italy

Azienda Ospedaleria San Camillo Forlanin

🇮🇹

Rome, Italy

Skane University Hospital

🇸🇪

Malmö, Sweden

Hospital de Donostia

🇪🇸

Donostia-San Sebastián, Spain

Haga ziekenhuis

🇳🇱

The Hague, Netherlands

Galway Clinic

🇮🇪

Galway, Ireland

University Hospital Galway

🇮🇪

Galway, Ireland

Radboud UMC

🇳🇱

Nijmegen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath